Puberty blockers and gender-affirming hormones are rarely prescribed to U.S. transgender and gender diverse (TGD) adolescents, according to a new study from researchers at Harvard T.H. Chan School of Public Health, Harvard Pilgrim Health Care Institute, and FOLX Health.